The Drug-Induced Respiratory Disease Website and App

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (ILD)

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (ILD), acute and/or severe (may cause ARDS)

I. Interstitial/parenchymal lung disease

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

I. Interstitial/parenchymal lung disease

I.d Acute eosinophilic pneumonia (AEP)

I. Interstitial/parenchymal lung disease

I.e Organizing pneumonia pattern (an area or areas of consolidation on imaging)

I. Interstitial/parenchymal lung disease

I.f Acute fibrinous organizing pneumonia (AFOP)

I. Interstitial/parenchymal lung disease

I.g Pulmonary fibrosis

I. Interstitial/parenchymal lung disease

I.i Subclinical pulmonary infiltrates/ILD

I. Interstitial/parenchymal lung disease

I.l Lung nodule or nodules

I. Interstitial/parenchymal lung disease

I.m Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)

I. Interstitial/parenchymal lung disease

I.t A mass or masses

I. Interstitial/parenchymal lung disease

I.v Relapsing or migrating pneumonitis/pneumonia (see also Id)

I. Interstitial/parenchymal lung disease

I.x Rapidly progressive ILD/pulmonary fibrosis (Hamman-Rich syndrome)

I. Interstitial/parenchymal lung disease

I.aa An area or areas of consolidation

I. Interstitial/parenchymal lung disease

I.ab Delayed ILD, -pneumonitis, -fibrosis

I. Interstitial/parenchymal lung disease

I.ap Pulmonary infiltrates

I. Interstitial/parenchymal lung disease

I.au Amiodarone pulmonary toxicity - Amiodarone lung

I. Interstitial/parenchymal lung disease

I.ay Chronic pneumonitis

I. Interstitial/parenchymal lung disease

I.az Unilateral interstitial lung disease

II. Pulmonary edema - Acute lung injury - ARDS

II.e ARDS - Acute lung injury

II. Pulmonary edema - Acute lung injury - ARDS

II.m Postoperative ARDS

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.a Alveolar hemorrhage (AH), diffuse AH (DAH)

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.c Hemoptysis

IV. Airway involvement

IV.a Bronchospasm - Wheezing - Asthma

IV. Airway involvement

IV.k Airway pigmentation (black, bluish, petechial)

IV. Airway involvement

IV.ab Cough (lone)

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.a Angioedema (may cause UAO, asphyxia and death)

VI. Pleural and/or pericardial involvement

VI.a Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

VI. Pleural and/or pericardial involvement

VI.c Pleural thickening - Fibrothorax

VI. Pleural and/or pericardial involvement

VI.d Pleural/pericardial effusion, ANA positive (DI lupus)

VI. Pleural and/or pericardial involvement

VI.u The apical cap

VII. Pulmonary vasculopathy

VII.a Pulmonary embolism - Venous thrombosis/thromboembolism

VII. Pulmonary vasculopathy

VII.i Acute pulmonary hypertension

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.a Diaphragm/inspiratory muscle weakness/paralysis (w/wo ARF)

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.d Respiratory failure from ventilatory depression (due to neuromuscular blockade/paralysis)

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.ai Acute respiratory failure (hypoxemia, acidosis) from myxedema (-coma)

X. Systemic/Distant conditions, syndromes and reactions

X.d Lupus - Lupus syndrome (see also Vd)

X. Systemic/Distant conditions, syndromes and reactions

X.f Anaphylaxis-Anaphylactoid reaction (can be fatal)

X. Systemic/Distant conditions, syndromes and reactions

X.s Systemic inflammatory response

XI. Miscellaneous

XI.c Pleuritic chest pain

XI. Miscellaneous

XI.g Bluish, pseudocyanotic skin discoloration

XII. Cardiovascular involvement / toxicity

XII.a Left or biventricular dysfunction/failure

XII. Cardiovascular involvement / toxicity

XII.c Pericardial effusion (w/wo tamponade)

XII. Cardiovascular involvement / toxicity

XII.f Takotsubo (stress) cardiomyopathy

XII. Cardiovascular involvement / toxicity

XII.n Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)

XII. Cardiovascular involvement / toxicity

XII.o Cardiovascular collapse - Cardiogenic shock - Hypotension

XII. Cardiovascular involvement / toxicity

XII.q QTc prolongation

XII. Cardiovascular involvement / toxicity

XII.v Torsades de pointe

XII. Cardiovascular involvement / toxicity

XII.ah Coronary vasospasm - Vasospastic angina

XII. Cardiovascular involvement / toxicity

XII.aw Heart failure (thyrotoxicosis-, thyroid storm-mediated)

XV. Pulmonary physiology - PFTs

XV.g Platypnea-orthodeoxia

XVI. Imaging

XVI.b Imaging: Ground-glass opacities (GGO) / shadowing

XVI. Imaging

XVI.i Imaging: An area or areas of involvement with a recognizable anatomic distribution

XVI. Imaging

XVI.j Imaging: Wandering (migratory) pulmonary opacities

XVI. Imaging

XVI.n Imaging: Intralobular septal thickening - Crazy paving

XVI. Imaging

XVI.s Imaging: An area or areas of involvement with high attenuation numbers or metallic density

XVI. Imaging

XVI.w Imaging: Lung nodule or nodules

XVI. Imaging

XVI.x Imaging: Waxing and waning nodules

XVI. Imaging

XVI.ab Imaging: Nodules, mass or masses with a central area of low attenuation (see also under XVIaa)

XVI. Imaging

XVI.ac Imaging: Cavitating/cavitary lung nodule, mass or nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp)

XVI. Imaging

XVI.ba Imaging: Asymmetrical, predominantly unilateral involvement

XVI. Imaging

XVI.bb Imaging: Solitary pulmonary nodule

XVI. Imaging

XVI.bn Imaging: Atelectasis (a combination of increased density and volume loss. Typically lobar)

XVI. Imaging

XVI.bt Imaging: A pattern consistent with pleuroparenchymal fibroelastosis

XVI. Imaging

XVI.bv Imaging: A subsolid lung nodule or nodules

XVI. Imaging

XVI.cb Imaging: Disseminated patchy pulmonary opacities

XVII. Distinctive patterns - 'Eye-catchers'

XVII.b Eye catcher: Electron-dense area or areas of consolidation on unenhanced chest CT

XVII. Distinctive patterns - 'Eye-catchers'

XVII.j Eye-catcher: Avid lung uptake on 18F-PET-CT

XVII. Distinctive patterns - 'Eye-catchers'

XVII.k Eye-catcher: An electron-dense liver on unenhanced CT

XVII. Distinctive patterns - 'Eye-catchers'

XVII.p Eye-catcher: An electron-dense ('white') thyroid

XVIII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XVIII.a BAL: An excess proportion of lymphocytes

XVIII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XVIII.b BAL: An excess proportion of neutrophils

XVIII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XVIII.c BAL: An excess proportion of eosinophils

XVIII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XVIII.e BAL: Stainable iron in macrophages

XVIII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XVIII.f BAL: Foamy macrophages

XVIII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XVIII.m BAL: A normal cell differential

XVIII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XVIII.p BAL: Lamellar bodies in AM on EM

XIX. Pathology

XIX.a Path: NSIP-cellular pattern (see also Ia, Ib)

XIX. Pathology

XIX.b Path: Eosinophilic pneumonia (subacute or acute) (see also Ic)

XIX. Pathology

XIX.c Path: Acute eosinophilic pneumonia pattern (see also under XVIb)

XIX. Pathology

XIX.d Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)

XIX. Pathology

XIX.e Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If)

XIX. Pathology

XIX.k Path: Desquamative interstitial pneumonia (DIP-pattern)

XIX. Pathology

XIX.o Path: Diffuse alveolar damage (DAD-pattern) (see also IL)

XIX. Pathology

XIX.q Path: Pneumocyte atypia (reactive epithelial cells) (a.k.a. the "Napoleon Hat" sign)

XIX. Pathology

XIX.r Path: Alveolar hemorrhage (see also IIIa)

XIX. Pathology

XIX.v Path: NSIP-fibrotic pattern

XIX. Pathology

XIX.w Path: Pulmonary fibrosis (UIP-pattern)

XIX. Pathology

XIX.aa Path: Endogenous lipoid pneumonia (phospholipidosis)

XIX. Pathology

XIX.ae Path: Foamy inclusions in alveolar macrophages and/or in other lung cells

XIX. Pathology

XIX.ag Path: Histiocytic proliferation

XIX. Pathology

XIX.aj Path: Lymphoid hyperplasia (including nodular- or a lymphocytic interstitial pneumonia pattern)

XIX. Pathology

XIX.ak Path: Smudged geographic necrosis

XIX. Pathology

XIX.bm Path: Pleuritis, pleural fibrosis

XX. Infections & related conditions

XX.e Pneumocystis jiroveci pneumonia

I. Interstitial/parenchymal lung disease

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

I. Interstitial/parenchymal lung disease

I.d Acute eosinophilic pneumonia (AEP)

I. Interstitial/parenchymal lung disease

I.e Organizing pneumonia pattern (an area or areas of consolidation on imaging)

I. Interstitial/parenchymal lung disease

I.u Pneumoconiosis (silicosis, talcosis...)

I. Interstitial/parenchymal lung disease

I.aa An area or areas of consolidation

II. Pulmonary edema - Acute lung injury - ARDS

II.a Pulmonary edema, noncardiogenic (NCPE)

II. Pulmonary edema - Acute lung injury - ARDS

II.b Pulmonary edema, cardiogenic

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.a Alveolar hemorrhage (AH), diffuse AH (DAH)

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.b Pneumorenal syndrome (w/wo ANCAs)

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.c Hemoptysis

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.n Alveolar hemorrhage (subclinical, or as a BAL feature)

IV. Airway involvement

IV.a Bronchospasm - Wheezing - Asthma

IV. Airway involvement

IV.b Severe or catastrophic bronchospasm or asthma attack (can be fatal)

IV. Airway involvement

IV.g Airway hyperresponsiveness

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.a Angioedema (may cause UAO, asphyxia and death)

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.c Upper airway obstruction other than angioedema or hematoma

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.l Midline destructive lesions

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.p Foreign body in the airway

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.q Drug foreign body in the airway

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.w Uvulitis, uvular edema

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.ai Tracheal polyps

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.aj Nasal, palatal and/or pharyngeal pathology

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.al Rhinitis medicamentosa

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.aq Airway foreign body

VI. Pleural and/or pericardial involvement

VI.f Pneumothorax

VI. Pleural and/or pericardial involvement

VI.ac Pneumothorax, bilateral

VII. Pulmonary vasculopathy

VII.a Pulmonary embolism - Venous thrombosis/thromboembolism

VII. Pulmonary vasculopathy

VII.b Pulmonary arterial hypertension

VII. Pulmonary vasculopathy

VII.l Acute pulmonary vasoconstriction and PHT

VIII. Mediastinal involvement

VIII.h Pneumomediastinum

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.k Trismus (lockjaw)

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.o Pneumorachis

X. Systemic/Distant conditions, syndromes and reactions

X.f Anaphylaxis-Anaphylactoid reaction (can be fatal)

X. Systemic/Distant conditions, syndromes and reactions

X.j Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)

X. Systemic/Distant conditions, syndromes and reactions

X.l Myopathy-Myositis-Polymyositis (see also under Xba)

X. Systemic/Distant conditions, syndromes and reactions

X.o Vascultis (pulmonary, extrathoracic or systemic)-ANCA status unknown or negative)

X. Systemic/Distant conditions, syndromes and reactions

X.q Neutrophilic dermatosis (Pyoderma, Sweet syndrome)

X. Systemic/Distant conditions, syndromes and reactions

X.u Vasculitis, pulmonary (w/wo AH), extrapulmonary, systemic: ANCA-positive

X. Systemic/Distant conditions, syndromes and reactions

X.w Multiple organ dysfunction/failure (MODS/MOF)

X. Systemic/Distant conditions, syndromes and reactions

X.z ANCA positivity. Subclinical or with clinical manifestations

X. Systemic/Distant conditions, syndromes and reactions

X.ae Anti-GBM antibody disease (Goodpasture-like or flare of preexisting GS)

X. Systemic/Distant conditions, syndromes and reactions

X.af Skin purpura, ecchymoses or necrosis

X. Systemic/Distant conditions, syndromes and reactions

X.au Scleroderma renal crisis

XI. Miscellaneous

XI.b Chest pain (acute or subacute), lone or prominent

XI. Miscellaneous

XI.k Pulmonary emphysema - Lung cysts or bullae

XI. Miscellaneous

XI.l Neutropenia, agranulocytosis (w/wo infection/sepsis)

XI. Miscellaneous

XI.o Death following exposure or poisoning

XI. Miscellaneous

XI.ab Barotrauma (incl. pneumothorax, pneumomediastinum, interstitial ephysema...)

XI. Miscellaneous

XI.au Sneezing (may cause pulmonary barotrauma)

XII. Cardiovascular involvement / toxicity

XII.a Left or biventricular dysfunction/failure

XII. Cardiovascular involvement / toxicity

XII.f Takotsubo (stress) cardiomyopathy

XII. Cardiovascular involvement / toxicity

XII.g Cardiomyopathy (acute, subacute, chronic)

XII. Cardiovascular involvement / toxicity

XII.h Coronary artery disease (acute) - Myocardial ischemia/infarction

XII. Cardiovascular involvement / toxicity

XII.n Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)

XII. Cardiovascular involvement / toxicity

XII.aa Pneumopericardium

XII. Cardiovascular involvement / toxicity

XII.ag Aortic dissection

XII. Cardiovascular involvement / toxicity

XII.ah Coronary vasospasm - Vasospastic angina

XII. Cardiovascular involvement / toxicity

XII.al Systemic arterial thrombosis

XII. Cardiovascular involvement / toxicity

XII.ar Coronary artery dissection

XIV. Hemoglobinopathies - Abnormal hemoglobin states (acquired)

XIV.b Carboxyhemoglobinemia

XVI. Imaging

XVI.k Imaging: An area or areas of consolidation

XIX. Pathology

XIX.b Path: Eosinophilic pneumonia (subacute or acute) (see also Ic)

XIX. Pathology

XIX.r Path: Alveolar hemorrhage (see also IIIa)

XIX. Pathology

XIX.t Path: Pulmonary edema (see also II/IIa)

XIX. Pathology

XIX.v Path: NSIP-fibrotic pattern

XIX. Pathology

XIX.ac Path: Pneumoconiosis (silicosis, talcosis, talcoma)

XIX. Pathology

XIX.cz Path: Skin vasculopathy/vasculitis/fibrin thrombi

XX. Infections & related conditions

XX.b Opportunistic pulmonary/systemic infections

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (ILD)

I. Interstitial/parenchymal lung disease

I.g Pulmonary fibrosis

I. Interstitial/parenchymal lung disease

I.k Exogenous lipoid pneumonia (subacute, acute)

I. Interstitial/parenchymal lung disease

I.aa An area or areas of consolidation

I. Interstitial/parenchymal lung disease

I.af Hydrocarbon pneumonitis

I. Interstitial/parenchymal lung disease

I.ag Chemical (toxic) pneumonitis

I. Interstitial/parenchymal lung disease

I.ah Fire-eater's lung/pneumonitis

II. Pulmonary edema - Acute lung injury - ARDS

II.e ARDS - Acute lung injury

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.a Alveolar hemorrhage (AH), diffuse AH (DAH)

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.c Hemoptysis

IV. Airway involvement

IV.j Bronchiectasis

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.i Thermal (burns, frostbite), chemical or caustic injury on the face, mouth, tongue, pharynx or upper airway

VI. Pleural and/or pericardial involvement

VI.a Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

XI. Miscellaneous

XI.b Chest pain (acute or subacute), lone or prominent

XI. Miscellaneous

XI.p Sniffing death - Death from inhalation of compound

XIV. Hemoglobinopathies - Abnormal hemoglobin states (acquired)

XIV.a Methemoglobinemia

XVI. Imaging

XVI.b Imaging: Ground-glass opacities (GGO) / shadowing

XVI. Imaging

XVI.f Imaging: Bibasilar opacities/shadowing

XVI. Imaging

XVI.k Imaging: An area or areas of consolidation

XVI. Imaging

XVI.ac Imaging: Cavitating/cavitary lung nodule, mass or nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp)

XVI. Imaging

XVI.ai Imaging: Pneumatoceles (see also XVIaf)

XVI. Imaging

XVI.aj Imaging: Pneumatocele or pneumatoceles

XVIII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XVIII.a BAL: An excess proportion of lymphocytes

XVIII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XVIII.h BAL: Exogenous (oil red O-stainable) lipids in BAL macrophages

XIX. Pathology

XIX.cd Path: Fire eater's lung

XX. Infections & related conditions

XX.p Lung abscess/abscesses (see also VIr)

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (ILD)

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (ILD), acute and/or severe (may cause ARDS)

I. Interstitial/parenchymal lung disease

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

I. Interstitial/parenchymal lung disease

I.e Organizing pneumonia pattern (an area or areas of consolidation on imaging)

I. Interstitial/parenchymal lung disease

I.m Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)

I. Interstitial/parenchymal lung disease

I.o Pulmonary alveolar proteinosis (PAP)

I. Interstitial/parenchymal lung disease

I.r Pulmonary nodulosis

I. Interstitial/parenchymal lung disease

I.z Progression, acceleration or exacerbation of preexisting ILD/fibrosis

I. Interstitial/parenchymal lung disease

I.aa An area or areas of consolidation

IV. Airway involvement

IV.ab Cough (lone)

VI. Pleural and/or pericardial involvement

VI.m Pleuropericarditis - Pleuropericardial effusion (ANA unknown or negative)

VII. Pulmonary vasculopathy

VII.b Pulmonary arterial hypertension

X. Systemic/Distant conditions, syndromes and reactions

X.a DRES syndrome - DRESS-like reaction

X. Systemic/Distant conditions, syndromes and reactions

X.d Lupus - Lupus syndrome (see also Vd)

XVIII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XVIII.a BAL: An excess proportion of lymphocytes

XIX. Pathology

XIX.a Path: NSIP-cellular pattern (see also Ia, Ib)

XIX. Pathology

XIX.d Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)

XIX. Pathology

XIX.o Path: Diffuse alveolar damage (DAD-pattern) (see also IL)

XIX. Pathology

XIX.q Path: Pneumocyte atypia (reactive epithelial cells) (a.k.a. the "Napoleon Hat" sign)

XX. Infections & related conditions

XX.g Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (ILD)

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (ILD), acute and/or severe (may cause ARDS)

I. Interstitial/parenchymal lung disease

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

I. Interstitial/parenchymal lung disease

I.d Acute eosinophilic pneumonia (AEP)

I. Interstitial/parenchymal lung disease

I.e Organizing pneumonia pattern (an area or areas of consolidation on imaging)

I. Interstitial/parenchymal lung disease

I.n ILD with a granulomatous component

I. Interstitial/parenchymal lung disease

I.aa An area or areas of consolidation

II. Pulmonary edema - Acute lung injury - ARDS

II.b Pulmonary edema, cardiogenic

IV. Airway involvement

IV.j Bronchiectasis

IV. Airway involvement

IV.l Large airway inflammation - Tracheitis (w/wo tissue eosinophilia)

IV. Airway involvement

IV.w Bronchiolitis (a clinical-imaging pattern suggestive of)

IV. Airway involvement

IV.x Obliterative bronchiolitis (a pattern consistent with) (see also IVn, XVx)

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.ax Tracheitis including eosinophilic tracheal inflammation

VI. Pleural and/or pericardial involvement

VI.a Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

VI. Pleural and/or pericardial involvement

VI.b Eosinophilic pleural effusion

VI. Pleural and/or pericardial involvement

VI.m Pleuropericarditis - Pleuropericardial effusion (ANA unknown or negative)

X. Systemic/Distant conditions, syndromes and reactions

X.a DRES syndrome - DRESS-like reaction

X. Systemic/Distant conditions, syndromes and reactions

X.d Lupus - Lupus syndrome (see also Vd)

XI. Miscellaneous

XI.b Chest pain (acute or subacute), lone or prominent

XII. Cardiovascular involvement / toxicity

XII.a Left or biventricular dysfunction/failure

XII. Cardiovascular involvement / toxicity

XII.c Pericardial effusion (w/wo tamponade)

XII. Cardiovascular involvement / toxicity

XII.d Myocarditis (can be fulminant)

XII. Cardiovascular involvement / toxicity

XII.h Coronary artery disease (acute) - Myocardial ischemia/infarction

XII. Cardiovascular involvement / toxicity

XII.i Eosinophilic myocarditis

XII. Cardiovascular involvement / toxicity

XII.o Cardiovascular collapse - Cardiogenic shock - Hypotension

XII. Cardiovascular involvement / toxicity

XII.r Pericarditis (see also under XIIc)

XII. Cardiovascular involvement / toxicity

XII.bi Myopericarditis (see under XIIc/d/g)

XVI. Imaging

XVI.b Imaging: Ground-glass opacities (GGO) / shadowing

XVI. Imaging

XVI.k Imaging: An area or areas of consolidation

XVI. Imaging

XVI.ba Imaging: Asymmetrical, predominantly unilateral involvement

XVIII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XVIII.a BAL: An excess proportion of lymphocytes

XVIII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XVIII.c BAL: An excess proportion of eosinophils

XIX. Pathology

XIX.a Path: NSIP-cellular pattern (see also Ia, Ib)

XIX. Pathology

XIX.b Path: Eosinophilic pneumonia (subacute or acute) (see also Ic)

XIX. Pathology

XIX.d Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)

XIX. Pathology

XIX.f Path: ILD with a granulomatous component (see also Im)

XIX. Pathology

XIX.aq Path: Obliterative (constrictive) bronchiolitis (see also IVc, IVn)

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (ILD)

I. Interstitial/parenchymal lung disease

I.g Pulmonary fibrosis

I. Interstitial/parenchymal lung disease

I.k Exogenous lipoid pneumonia (subacute, acute)

I. Interstitial/parenchymal lung disease

I.l Lung nodule or nodules

I. Interstitial/parenchymal lung disease

I.t A mass or masses

I. Interstitial/parenchymal lung disease

I.aa An area or areas of consolidation

I. Interstitial/parenchymal lung disease

I.aq Paraffinoma - Lipidoma (ELP in the form of a nodule or mass)

II. Pulmonary edema - Acute lung injury - ARDS

II.e ARDS - Acute lung injury

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.c Hemoptysis

IV. Airway involvement

IV.r Plugs/casts in the airways

VIII. Mediastinal involvement

VIII.p Lipid-laden mediastinal lymphadenopathy

X. Systemic/Distant conditions, syndromes and reactions

X.e Autoimmunity-Autoimmune conditions (+ANA, +anti-ds-DNA, +ANCAs, other auto-Abs)

XVI. Imaging

XVI.a Imaging: Diffuse haze

XVI. Imaging

XVI.b Imaging: Ground-glass opacities (GGO) / shadowing

XVI. Imaging

XVI.f Imaging: Bibasilar opacities/shadowing

XVI. Imaging

XVI.i Imaging: An area or areas of involvement with a recognizable anatomic distribution

XVI. Imaging

XVI.k Imaging: An area or areas of consolidation

XVI. Imaging

XVI.n Imaging: Intralobular septal thickening - Crazy paving

XVI. Imaging

XVI.r Imaging: An area or areas of involvement with low attenuation numbers

XVI. Imaging

XVI.w Imaging: Lung nodule or nodules

XVI. Imaging

XVI.aa Imaging: A large nodule or a mass

XVI. Imaging

XVI.ac Imaging: Cavitating/cavitary lung nodule, mass or nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp)

XVI. Imaging

XVI.bb Imaging: Solitary pulmonary nodule

XVI. Imaging

XVI.be Imaging: Intrathoracic lymph node enlargement

XVII. Distinctive patterns - 'Eye-catchers'

XVII.r Eye catcher: A milky, cloudy or lumpy BAL fluid

XVIII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XVIII.a BAL: An excess proportion of lymphocytes

XVIII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XVIII.h BAL: Exogenous (oil red O-stainable) lipids in BAL macrophages

XVIII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XVIII.j BAL: Free exogenous lipids in supernatant

XIX. Pathology

XIX.f Path: ILD with a granulomatous component (see also Im)

XIX. Pathology

XIX.v Path: NSIP-fibrotic pattern

XIX. Pathology

XIX.z Path: Exogenous lipoid pneumonia

XIX. Pathology

XIX.ab Path: Foreign body deposits/granulomatous reaction

XIX. Pathology

XIX.de Path: Exogenous lipid-laden lymphadenopathy

XX. Infections & related conditions

XX.h Nontuberculous pulmonary mycobacterial infection/superinfection

XXI. Neoplastic conditions

XXI.a Lung cancer

XXVI. Veterinary medicine

XXVI.c Veterinary: Exogenous lipoid pneumonia

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (ILD)

I. Interstitial/parenchymal lung disease

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

I. Interstitial/parenchymal lung disease

I.e Organizing pneumonia pattern (an area or areas of consolidation on imaging)

I. Interstitial/parenchymal lung disease

I.i Subclinical pulmonary infiltrates/ILD

I. Interstitial/parenchymal lung disease

I.p Focal/localized area of pneumonitis/fibrosis

I. Interstitial/parenchymal lung disease

I.v Relapsing or migrating pneumonitis/pneumonia (see also Id)

I. Interstitial/parenchymal lung disease

I.w Abnormal lung function/pulmonary physiology (PFTs) without necessarily imaging or clinical evidence

I. Interstitial/parenchymal lung disease

I.aa An area or areas of consolidation

VI. Pleural and/or pericardial involvement

VI.u The apical cap

XII. Cardiovascular involvement / toxicity

XII.b Valvular heart disease and/or dysfunction

XII. Cardiovascular involvement / toxicity

XII.c Pericardial effusion (w/wo tamponade)

XII. Cardiovascular involvement / toxicity

XII.p Coronary artery disease (subacute, chronic)

XVI. Imaging

XVI.i Imaging: An area or areas of involvement with a recognizable anatomic distribution

XVIII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XVIII.a BAL: An excess proportion of lymphocytes

XIX. Pathology

XIX.d Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)

XXI. Neoplastic conditions

XXI.a Lung cancer

XXI. Neoplastic conditions

XXI.m Tumor of the heart

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (ILD)

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (ILD), acute and/or severe (may cause ARDS)

I. Interstitial/parenchymal lung disease

I.l Lung nodule or nodules

I. Interstitial/parenchymal lung disease

I.aa An area or areas of consolidation

I. Interstitial/parenchymal lung disease

I.am Silicone pneumonitis - 'Silicone lung'

II. Pulmonary edema - Acute lung injury - ARDS

II.e ARDS - Acute lung injury

II. Pulmonary edema - Acute lung injury - ARDS

II.u Acute respiratory failure (e.g. from ARDS, ILD, PIE, OP, pulmonary edema or bronchospasm) requiring ECMO

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.a Alveolar hemorrhage (AH), diffuse AH (DAH)

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.n Submucosal airway petechiae/hemorrhage

VII. Pulmonary vasculopathy

VII.m Silicone pulmonary embolism (SE) - SE syndrome

VIII. Mediastinal involvement

VIII.k Mediastinal silicone infiltration/siliconoma

X. Systemic/Distant conditions, syndromes and reactions

X.w Multiple organ dysfunction/failure (MODS/MOF)

XI. Miscellaneous

XI.b Chest pain (acute or subacute), lone or prominent

XI. Miscellaneous

XI.d A restrictive lung function defect

XI. Miscellaneous

XI.x CNS symptoms or involvement, stroke

XI. Miscellaneous

XI.bk Parietal chest involvement

XVI. Imaging

XVI.b Imaging: Ground-glass opacities (GGO) / shadowing

XVI. Imaging

XVI.e Imaging: Pulmonary opacities with a subpleural distribution

XVI. Imaging

XVI.k Imaging: An area or areas of consolidation

XVI. Imaging

XVI.az Imaging: Foreign body pulmonary embolism

XVI. Imaging

XVI.bk Imaging: F18-PET scan positive lympadenopathy

XVIII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XVIII.d BAL: Gross or microscopic bleeding/hemorrhage

XVIII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XVIII.l BAL: Silicone globules in macrophages

XIX. Pathology

XIX.d Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)

XIX. Pathology

XIX.o Path: Diffuse alveolar damage (DAD-pattern) (see also IL)

XIX. Pathology

XIX.r Path: Alveolar hemorrhage (see also IIIa)

XIX. Pathology

XIX.x Path: Pulmonary fibrosis (not otherwise specified or unclassifiable)

XIX. Pathology

XIX.af Path: Silicone droplets/vacuoles in lung tissue, pulmonary vasculature, or lymph nodes

XIX. Pathology

XIX.bh Path: Silicone pulmonary embolism

XIX. Pathology

XIX.ch Path: Siliconoma

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (ILD)

I. Interstitial/parenchymal lung disease

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

I. Interstitial/parenchymal lung disease

I.d Acute eosinophilic pneumonia (AEP)

I. Interstitial/parenchymal lung disease

I.e Organizing pneumonia pattern (an area or areas of consolidation on imaging)

I. Interstitial/parenchymal lung disease

I.z Progression, acceleration or exacerbation of preexisting ILD/fibrosis

I. Interstitial/parenchymal lung disease

I.aa An area or areas of consolidation

II. Pulmonary edema - Acute lung injury - ARDS

II.e ARDS - Acute lung injury

VI. Pleural and/or pericardial involvement

VI.a Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

VII. Pulmonary vasculopathy

VII.a Pulmonary embolism - Venous thrombosis/thromboembolism

VII. Pulmonary vasculopathy

VII.e Fat/oil embolism - The FES embolism syndrome

VII. Pulmonary vasculopathy

VII.t Foreign body/substance pulmonary embolism

VII. Pulmonary vasculopathy

VII.z Lipiodol pulmonary embolism

XI. Miscellaneous

XI.x CNS symptoms or involvement, stroke

XVI. Imaging

XVI.s Imaging: An area or areas of involvement with high attenuation numbers or metallic density

XVII. Distinctive patterns - 'Eye-catchers'

XVII.h Eye-catcher: Lipiodol embolism

XIX. Pathology

XIX.d Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)